Insights
Search Results
News Articles
6.05.26
Wilson Sonsini Attorneys Named to Lawdragon’s 2026 List of Next-Generation Lawyers
Ten Wilson Sonsini attorneys have been recognized in the 2026 edition of Lawdragon 500 X – The Next Generation. Individuals listed in the guide are “the future of the law” and are recognized for their accomplishments in their career thus far.
Client Highlights
5.11.26
Wilson Sonsini Advises Odyssey Therapeutics on Patent Matters Related to IPO
On May 7, 2026, Odyssey Therapeutics, a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that are designed to precisely target disease pathology, announced the pricing of its upsized initial public offering of 15,500,000 shares of its common stock at an initial public offering price of $18.00 per share. In addition, Odyssey has granted the underwriters a 30-day option to purchase up to an additional 2,325,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. Odyssey’s common stock began trading on the Nasdaq Capital Market on May 8, 2026, under the ticker symbol “ODTX.” The offering closed on May 11, 2026. Wilson Sonsini Goodrich & Rosati advised Odyssey on patent matters related to the transaction.
News Articles
10.21.25
San Diego Business Journal Names Deborah Smith Among 2025 Leaders of Influence in Law
On October 20, 2025, Wilson Sonsini partner Deborah Smith was honored among the 2025 “Leaders of Influence in Law” in San Diego Business Journal’s special supplement.
Client Highlights
9.05.25
Firm Advises Enlaza on IP Matters Related to Multi-Target Drug Discovery Collaboration with Vertex Pharmaceuticals
On September 2, 2025, Enlaza Therapeutics, the first covalent biologics platform company, announced a multi-target drug discovery collaboration with Vertex Pharmaceuticals to utilize Enlaza’s proprietary War-Lock™ technology platform to develop small format drug conjugates and T-cell engagers for certain autoimmune diseases and improved conditioning in sickle cell disease and beta thalassemia. Wilson Sonsini Goodrich & Rosati advised Enlaza on IP matters related to the transaction.
News Articles
7.11.25
Lawdragon Names 12 Wilson Sonsini Lawyers to Its 2025 List of Next-Generation Lawyers
Twelve Wilson Sonsini attorneys have been recognized in the 2025 Lawdragon 500 X – The Next Generation, the third edition of the guide. Individuals listed in the guide traditionally have “proven themselves early in private practice, accruing credentials, deals, and cases early and often,” with the majority of lawyers having been in practice between seven and fifteen years.
7.29.24
Firm Advises Nerio on IP Matters Related to $1.3 Billion Acquisition by Boehringer
On July 29, 2024, biopharmaceutical company Boehringer Ingelheim announced its acquisition of Nerio Therapeutics, a drug discovery and development company focused on phosphatases, a notoriously difficult class of potentially high-value therapeutic protein targets, and its preclinical program of novel immune checkpoint inhibitors for up to $1.3 billion. Wilson Sonsini Goodrich & Rosati advised Nerio Therapeutics on IP related to the transaction and advises the company on patent matters.
Client Highlights
5.01.24
Wilson Sonsini Advises Enlaza Therapeutics on IP Matters Related to $100 Million Series A
On April 30, 2024, Enlaza Therapeutics (Enlaza), the first covalent biologic platform company, announced it successfully closed a $100 million Series A financing. The round was led by the Life Sciences group of J.P. Morgan Asset Management’s Private Capital division, with participation from existing investors Frazier Life Sciences, Avalon Ventures, Lightspeed Venture Partners, and Samsara BioCapital. The financing also includes new investors Amgen Ventures, Regeneron Ventures, Bregua Corporation, Pappas Capital, and Alexandria Venture Investments. Wilson Sonsini Goodrich & Rosati advised Enlaza on IP matters related to the Series A and represents the company in patent strategy and prosecution matters.
Client Highlights
4.11.24
Wilson Sonsini Advises Boundless Bio on IP Matters Related to IPO
On March 27, 2024, Boundless Bio, a clinical stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, announced the pricing of its initial public offering of 6,250,000 shares of its common stock at an initial public offering price of $16.00 per share. All of the shares were offered by Boundless Bio. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be $100.0 million. Boundless Bio’s common stock began trading on the Nasdaq Global Select Market on March 28, 2024, under the ticker symbol “BOLD," and closed on April 2, 2024. In addition, Boundless Bio has granted the underwriters a 30-day option to purchase up to an additional 937,500 shares of common stock at the initial public offering price, less underwriting discounts and commissions.
Client Highlights
4.03.24
Wilson Sonsini Advises Alterome on $132 Million Series B
On April 3, 2024, Alterome Therapeutics, Inc., a biopharmaceutical company pioneering the development of next generation, small molecule targeted therapies for the treatment of cancer, announced the closing of a $132 million Series B financing. The financing was led by Goldman Sachs Alternatives, with participation by Canaan Partners, Invus, Driehaus Capital Management, Digitalis Ventures, Blue Owl Capital, and existing investors Orbimed, Nextech Invest, Vida Ventures, Boxer Capital, and Colt Ventures. Wilson Sonsini Goodrich & Rosati advised Alterome on the transaction.
Client Highlights
2.20.24
Wilson Sonsini Advises Kinnate Biopharma on Acquisition By XOMA
On February 16, 2024, Kinnate Biopharma Inc., a clinical-stage precision oncology company, announced it has entered into a definitive merger agreement whereby XOMA Corporation will acquire Kinnate. Pursuant and subject to the terms of the merger agreement, a wholly owned subsidiary of XOMA will commence a tender offer by March 4, 2024 to acquire all outstanding shares of Kinnate common stock. The merger transaction is expected to close in the first half of 2024. Wilson Sonsini Goodrich & Rosati is advising Kinnate on the transaction.